{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:59:07Z","timestamp":1781305147987,"version":"3.54.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11394-2","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T05:32:06Z","timestamp":1766986326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distinct origins of high-grade serous ovarian carcinoma: genetic and epigenetic evidence linking ovarian and fallopian tube epithelium to clinical outcomes and early detection"],"prefix":"10.1007","volume":"53","author":[{"given":"Mohammad","family":"Ghanbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Aghazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitham","family":"Alhajamee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ismael Ibrahim","family":"Jebur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheyaa Obaid","family":"Alamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Mutashar","family":"Ghalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Haghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"11","key":"11394_CR1","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/ijc.30676","volume":"140","author":"S Coburn","year":"2017","unstructured":"Coburn S, Bray F, Sherman M, Trabert B (2017) International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer 140(11):2451\u20132460","journal-title":"Int J Cancer"},{"key":"11394_CR2","doi-asserted-by":"crossref","unstructured":"Caruso G, Weroha SJ, Cliby W (2025) Ovarian cancer: a review. Jama 334(14):1278-129","DOI":"10.1001\/jama.2025.9495"},{"issue":"1","key":"11394_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer Stat, 2025. Ca 75(1):10","journal-title":"Ca"},{"key":"11394_CR4","doi-asserted-by":"crossref","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY (2016) Ovarian cancer (Primer). Nat Reviews: Disease Primers 2(1)","DOI":"10.1038\/nrdp.2016.61"},{"issue":"21","key":"11394_CR5","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1038\/s41388-020-1288-2","volume":"39","author":"T Kan","year":"2020","unstructured":"Kan T, Wang W, Ip PP, Zhou S, Wong AS, Wang X et al (2020) Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer Ascites. Oncogene 39(21):4227\u20134240","journal-title":"Oncogene"},{"issue":"1","key":"11394_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/nyas.14748","volume":"1512","author":"C Liu","year":"2022","unstructured":"Liu C, Zhang Y, Li X, Wang D (2022) Ovarian cancer-specific dysregulated genes with prognostic significance: scRNA-Seq with bulk RNA-Seq data and experimental validation. Annals of the New York Academy of Sciences 1512(1):154\u2013173","journal-title":"Annals of the New York Academy of Sciences"},{"key":"11394_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdt463","volume":"24","author":"R Kurman","year":"2013","unstructured":"Kurman R (2013) Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Annals of oncology. 24:16\u201321","journal-title":"Annals of oncology."},{"issue":"20","key":"11394_CR8","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-18-0784","volume":"24","author":"GM Chen","year":"2018","unstructured":"Chen GM, Kannan L, Geistlinger L, Kofia V, Safikhani Z, Gendoo DM et al (2018) Consensus on molecular subtypes of high-grade serous ovarian carcinoma. Clin Cancer Res 24(20):5037\u20135047","journal-title":"Clin Cancer Res"},{"issue":"10","key":"11394_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD et al (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11(10): 719\u2013725","journal-title":"Nat Rev Cancer"},{"issue":"5\u20136","key":"11394_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1155\/2007\/309382","volume":"23","author":"D Badgwell","year":"2007","unstructured":"Badgwell D, Bast RC Jr (2007) Early detection of ovarian cancer. Disease markers. 23(5\u20136):397\u2013410","journal-title":"Disease markers."},{"issue":"1","key":"11394_CR11","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1038\/s41467-019-13116-2","volume":"10","author":"S Zhang","year":"2019","unstructured":"Zhang S, Dolgalev I, Zhang T, Ran H, Levine DA, Neel BG (2019) Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Nat Commun 10(1):5367","journal-title":"Nat Commun"},{"key":"11394_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M et al (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8:1","journal-title":"Nat Commun"},{"issue":"2","key":"11394_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","volume":"31","author":"DW Kindelberger","year":"2007","unstructured":"Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F et al (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31(2):161\u2013169","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"11394_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41379-019-0370-1","volume":"33","author":"N-YY Wu","year":"2020","unstructured":"Wu N-YY, Fang C, Huang H-S, Wang J, Chu T-Y (2020) Natural history of ovarian high-grade serous carcinoma from time effects of ovulation Inhibition and progesterone clearance of p53-defective lesions. Mod Pathol 33(1):29\u201337","journal-title":"Mod Pathol"},{"issue":"5","key":"11394_CR15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3390\/cancers12051090","volume":"12","author":"R Sowamber","year":"2020","unstructured":"Sowamber R, Nelson O, Dodds L, Decastro V, Paudel I, Milea A et al (2020) Integrative transcriptome analyses of the human fallopian tube: fimbria and ampulla\u2014site of origin of serous carcinoma of the ovary. Cancers. 12(5):1090","journal-title":"Cancers."},{"issue":"1","key":"11394_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s42003-025-07871-w","volume":"8","author":"J Sipes","year":"2025","unstructured":"Sipes J, Rayamajhi S, Bantis LE, Madan R, Mitra A, Puri RV et al (2025) Spatial transcriptomic profiling of the human fallopian tube epithelium reveals region-specific gene expression patterns. Commun Biology 8(1):520","journal-title":"Commun Biology"},{"key":"11394_CR17","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1158\/1078-0432.CCR-07-4959","volume":"14","author":"AA Tone","year":"2008","unstructured":"Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ et al (2008) Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clinical cancer research. 14:4067\u20134078","journal-title":"Clinical cancer research."},{"key":"11394_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ijgo.12614","volume":"143","author":"JS Berek","year":"2018","unstructured":"Berek JS, Kehoe ST, Kumar L, Friedlander M (2018) Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 143:59\u201378","journal-title":"Int J Gynecol Obstet"},{"issue":"7353","key":"11394_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"CGAR Network","year":"2011","unstructured":"Network CGAR (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609","journal-title":"Nature"},{"issue":"3","key":"11394_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/path.3023","volume":"226","author":"E Kuhn","year":"2012","unstructured":"Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R et al (2012) TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma\u2014evidence supporting the clonal relationship of the two lesions. J Pathol 226(3):421\u2013426","journal-title":"J Pathol"},{"issue":"1","key":"11394_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M et al (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8(1):1\u201311","journal-title":"Nat Commun"},{"issue":"11","key":"11394_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/cancers10110433","volume":"10","author":"J Kim","year":"2018","unstructured":"Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho C-H et al (2018) Cell origins of high-grade serous ovarian cancer. Cancers. 10(11):433","journal-title":"Cancers."},{"issue":"1","key":"11394_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/his.14902","volume":"83","author":"JM Bogaerts","year":"2023","unstructured":"Bogaerts JM, Van Bommel MH, Hermens RP, Steenbeek MP, De Hullu JA, Van Der Laak JA et al (2023) Consensus based recommendations for the diagnosis of serous tubal intraepithelial carcinoma: an international Delphi study. Histopathology 83(1):67\u201379","journal-title":"Histopathology"},{"key":"11394_CR24","doi-asserted-by":"publisher","DOI":"10.2527\/af.2015-0005","volume-title":"The oviduct A key organ for the success of early reproductive events","author":"M Avil\u00e9s","year":"2015","unstructured":"Avil\u00e9s M, Coy P, Rizos D (2015) The oviduct A key organ for the success of early reproductive events. Departamento de Reproducci\u00f3n Animal"},{"key":"11394_CR25","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/onc.2009.402","volume":"29","author":"K Levanon","year":"2010","unstructured":"Levanon K, Ng V, Piao H-Y, Zhang Y, Chang MC, Roh MH et al (2010) Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 29:8, 1103\u20131113","journal-title":"Oncogene"},{"issue":"2","key":"11394_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ygyno.2006.08.052","volume":"104","author":"NJ Bowen","year":"2007","unstructured":"Bowen NJ, Logani S, Dickerson EB, Kapa LB, Akhtar M, Benigno BB et al (2007) Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecologic oncology. 104(2):331\u2013337","journal-title":"Gynecologic oncology."},{"issue":"21","key":"11394_CR27","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.3390\/ijms20215482","volume":"20","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Obata T, Daikoku T, Fujiwara H (2019) The association and significance of p53 in gynecologic cancers: the potential of targeted therapy. Int J Mol Sci 20(21):5482","journal-title":"Int J Mol Sci"},{"key":"11394_CR28","doi-asserted-by":"publisher","first-page":"886533","DOI":"10.3389\/fendo.2022.886533","volume":"13","author":"SJ Ritch","year":"2022","unstructured":"Ritch SJ, Telleria CM (2022) The transcoelomic ecosystem and epithelial ovarian cancer dissemination. Front Endocrinol. 13:886533","journal-title":"Front Endocrinol."},{"issue":"6","key":"11394_CR29","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/cancers11060838","volume":"11","author":"N Loret","year":"2019","unstructured":"Loret N, Denys H, Tummers P, Berx G (2019) The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. Cancers. 11(6):838","journal-title":"Cancers."},{"key":"11394_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mehy.2017.07.014","volume":"107","author":"J Rohozinski","year":"2017","unstructured":"Rohozinski J, Diaz-Arrastia C, Edwards CL (2017) Do some epithelial ovarian cancers originate from a fallopian tube ciliate cell lineage? Med Hypotheses 107:16\u201321","journal-title":"Med Hypotheses"},{"issue":"11","key":"11394_CR31","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/stem.1207","volume":"30","author":"DY Paik","year":"2012","unstructured":"Paik DY, Janzen DM, Schafenacker AM, Velasco VS, Shung MS, Cheng D et al (2012) Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation. Stem cells. 30(11):2487\u20132497","journal-title":"Stem cells."},{"issue":"1","key":"11394_CR32","doi-asserted-by":"publisher","first-page":"8641","DOI":"10.1038\/s41467-024-52984-1","volume":"15","author":"A Flesken-Nikitin","year":"2024","unstructured":"Flesken-Nikitin A, Ralston CQ, Fu D-J, De Micheli AJ, Phuong DJ, Harlan BA et al (2024) Pre-ciliated tubal epithelial cells are prone to initiation of high-grade serous ovarian carcinoma. Nat Commun 15(1):8641","journal-title":"Nat Commun"},{"issue":"1","key":"11394_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1196\/annals.1322.015","volume":"1028","author":"M Rossi","year":"2004","unstructured":"Rossi M, Sayan AE, Terrinoni A, Melino G, Knight RA (2004) Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology. Annals of the New York Academy of Sciences. 1028(1):143\u2013149","journal-title":"Annals of the New York Academy of Sciences."},{"issue":"12","key":"11394_CR34","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/sj.cdd.4401774","volume":"12","author":"M M\u00fcller","year":"2005","unstructured":"M\u00fcller M, Schilling T, Sayan A, Kairat A, Lorenz K, Schulze-Bergkamen H et al (2005) TAp73\/\u2206Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 12(12):1564\u20131577","journal-title":"Cell Death Differ"},{"key":"11394_CR35","doi-asserted-by":"publisher","unstructured":"Metousis A, Kenny HA, Shimizu A, Schweizer L, Ben-Moshe S, Bilecz A et al (2025) Integration of cell-type resolved Spatial proteomics and transcriptomics reveals novel mechanisms in early ovarian cancer. MedRxiv  https:\/\/doi.org\/10.1101\/2025.08.25.25333715","DOI":"10.1101\/2025.08.25.25333715"},{"key":"11394_CR36","doi-asserted-by":"crossref","unstructured":"Makhmut A, Dragomir MP, Fritzsche S, Moebs M, Schmitt WD, Taube ET et al (2025) Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets. Molecular systems biology. 1-35.","DOI":"10.1038\/s44320-025-00168-4"},{"issue":"3","key":"11394_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih I-M (2010) The origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. The American journal of surgical pathology. 34(3):433","journal-title":"The American journal of surgical pathology."},{"issue":"2","key":"11394_CR38","first-page":"255","volume":"22","author":"N Auersperg","year":"2001","unstructured":"Auersperg N, Wong AS, Choi K-C, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocrine reviews. 22(2):255\u2013288","journal-title":"Endocrine reviews."},{"issue":"8","key":"11394_CR39","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1210\/en.2007-0030","volume":"148","author":"JE Burdette","year":"2007","unstructured":"Burdette JE, Oliver RM, Ulyanov V, Kilen SM, Mayo KE, Woodruff TK (2007) Ovarian epithelial inclusion cysts in chronically superovulated CD1 and Smad2 dominant-negative mice. Endocrinology. 148(8):3595\u20133604","journal-title":"Endocrinology."},{"issue":"8","key":"11394_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/cancers9080104","volume":"9","author":"Y Klymenko","year":"2017","unstructured":"Klymenko Y, Kim O, Stack MS (2017) Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer. Cancers. 9(8):104","journal-title":"Cancers."},{"issue":"5","key":"11394_CR41","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1093\/carcin\/bgt003","volume":"34","author":"SM King","year":"2013","unstructured":"King SM, Quartuccio SM, Vanderhyden BC, Burdette JE (2013) Early transformative changes in normal ovarian surface epithelium induced by oxidative stress require Akt upregulation, DNA damage and epithelial\u2013stromal interaction. Carcinogenesis. 34(5):1125\u20131133","journal-title":"Carcinogenesis."},{"key":"11394_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nature11979","volume":"495","author":"A Flesken-Nikitin","year":"2013","unstructured":"Flesken-Nikitin A, Hwang C-I, Cheng C-Y, Michurina TV, Enikolopov G, Nikitin AY (2013) Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 495:7440, 241\u2013245","journal-title":"Nature"},{"key":"11394_CR43","doi-asserted-by":"crossref","unstructured":"Yamulla RJ, Nalubola S, Flesken-Nikitin A, Nikitin AY, Schimenti JC (2020) Most commonly mutated genes in high-grade serous ovarian carcinoma are nonessential for ovarian surface epithelial stem cell transformation. Cell Rep. 32(9)","DOI":"10.1016\/j.celrep.2020.108086"},{"issue":"9","key":"11394_CR44","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/modpathol.2017.53","volume":"30","author":"E Schmoeckel","year":"2017","unstructured":"Schmoeckel E, Odai-Afotey AA, Schlei\u00dfheimer M, Rottmann M, Flesken-Nikitin A, Ellenson LH et al (2017) LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions. Mod Pathol 30(9):1241\u20131250","journal-title":"Mod Pathol"},{"issue":"1","key":"11394_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R et al (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221(1):49\u201356","journal-title":"J Pathol"},{"issue":"1","key":"11394_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/cdd.2017.169","volume":"25","author":"BJ Aubrey","year":"2018","unstructured":"Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A (2018) How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell death & differentiation. 25(1):104\u2013113","journal-title":"Cell death & differentiation."},{"key":"11394_CR47","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW (2017) Putting p53 in context. Cell. 170:1062\u20131078","journal-title":"Cell."},{"issue":"13","key":"11394_CR48","first-page":"3459","volume":"63","author":"A Flesken-Nikitin","year":"2003","unstructured":"Flesken-Nikitin A, Choi K-C, Eng JP, Shmidt EN, Nikitin AY (2003) Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 63(13):3459\u20133463","journal-title":"Cancer Res"},{"issue":"16","key":"11394_CR49","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1158\/0008-5472.CAN-11-3834","volume":"72","author":"L Szabova","year":"2012","unstructured":"Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB et al (2012) Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 72(16):4141\u20134153","journal-title":"Cancer Res"},{"issue":"12","key":"11394_CR50","doi-asserted-by":"publisher","first-page":"e8404","DOI":"10.1371\/journal.pone.0008404","volume":"4","author":"BA Quinn","year":"2009","unstructured":"Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH et al (2009) Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS ONE 4(12):e8404","journal-title":"PLoS ONE"},{"issue":"12","key":"11394_CR51","doi-asserted-by":"publisher","first-page":"e8534","DOI":"10.1371\/journal.pone.0008534","volume":"4","author":"KV Clark-Knowles","year":"2009","unstructured":"Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC (2009) Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PloS One 4(12):e8534","journal-title":"PloS One"},{"issue":"23","key":"11394_CR52","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.1158\/1078-0432.CCR-17-0638","volume":"23","author":"D Hao","year":"2017","unstructured":"Hao D, Li J, Jia S, Meng Y, Zhang C, Wang L et al (2017) Integrated analysis reveals tubal-and ovarian-originated serous ovarian cancer and predicts differential therapeutic responses. Clin Cancer Res 23(23):7400\u20137411","journal-title":"Clin Cancer Res"},{"issue":"5","key":"11394_CR53","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0002-9378(11)91730-X","volume":"167","author":"PA Kruk","year":"1992","unstructured":"Kruk PA, Auersperg N (1992) Human ovarian surface epithelial cells are capable of physically restructuring extracellular matrix. Am J Obstet Gynecol 167(5):1437\u20131443","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"11394_CR54","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/path.5752","volume":"255","author":"Y Maru","year":"2021","unstructured":"Maru Y, Tanaka N, Tatsumi Y, Nakamura Y, Yao R, Noda T et al (2021) Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids. J Pathol 255(2):177\u2013189","journal-title":"J Pathol"},{"issue":"2","key":"11394_CR55","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3390\/ijms25020886","volume":"25","author":"Y Dai","year":"2024","unstructured":"Dai Y, Xu J, Gong X, Wei J, Gao Y, Chai R et al (2024) Human fallopian tube-derived organoids with TP53 and RAD51D mutations recapitulate an early stage high-grade serous ovarian cancer phenotype in vitro. International Journal of Molecular Sciences. 25(2):886","journal-title":"International Journal of Molecular Sciences."},{"issue":"9","key":"11394_CR56","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1158\/2767-9764.CRC-24-0144","volume":"4","author":"A Blackman","year":"2024","unstructured":"Blackman A, Rees AC, Bowers RR, Jones CM, Vaena SG, Clark MA et al (2024) MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53\u2013R270H mouse model. Cancer research communications. 4(9):2525\u20132538","journal-title":"Cancer research communications."},{"issue":"5","key":"11394_CR57","first-page":"7769","volume":"15","author":"L Xiang","year":"2018","unstructured":"Xiang L, Rong G, Zhao J, Wang Z, Shi F (2018) Identification of candidate genes associated with tubal origin of high\u2013grade serous ovarian cancer. Oncol Lett 15(5):7769\u20137775","journal-title":"Oncol Lett"},{"issue":"8","key":"11394_CR58","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/ijc.30591","volume":"140","author":"FH Tang","year":"2017","unstructured":"Tang FH, Hsieh TH, Hsu CY, Lin HY, Long CY, Cheng KH et al (2017) KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice. Int J Cancer 140(8):1860\u20131869","journal-title":"Int J Cancer"},{"issue":"5","key":"11394_CR59","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/biolre\/ioaa008","volume":"102","author":"M Shi","year":"2020","unstructured":"Shi M, Whorton AE, Sekulovski N, Paquet M, Maclean JA, Song Y et al (2020) Inactivation of TRP53, PTEN, RB1, and\/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis. Biology of reproduction. 102(5):1055\u20131064","journal-title":"Biology of reproduction."},{"key":"11394_CR60","doi-asserted-by":"crossref","unstructured":"Galhenage P, Zhou Y, Perry E, Loc B, Fietz K, Iyer S et al (2023) Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer. Cell Rep. 42(10)","DOI":"10.1016\/j.celrep.2023.113144"},{"issue":"20","key":"11394_CR61","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1158\/0008-5472.CAN-20-1518","volume":"81","author":"K Teng","year":"2021","unstructured":"Teng K, Ford MJ, Harwalkar K, Li Y, Pacis AS, Farnell D et al (2021) Modeling High-Grade serous ovarian carcinoma using a combination of in vivo fallopian tube electroporation and CRISPR-Cas9\u2013Mediated genome editing. Cancer Res 81(20):5147\u20135160","journal-title":"Cancer Res"},{"issue":"1","key":"11394_CR62","doi-asserted-by":"publisher","first-page":"12645","DOI":"10.1038\/ncomms12645","volume":"7","author":"F Coscia","year":"2016","unstructured":"Coscia F, Watters K, Curtis M, Eckert M, Chiang C, Tyanova S et al (2016) Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun 7(1):12645","journal-title":"Nat Commun"},{"key":"11394_CR63","doi-asserted-by":"crossref","unstructured":"Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C et al (2016) The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype\u2013specific therapeutic target for ovarian cancer. Sci Signal 9(448):ra97\u2013ra97","DOI":"10.1126\/scisignal.aaf8175"},{"issue":"3","key":"11394_CR64","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1078-0432.CCR-13-1256","volume":"20","author":"D-J Cheon","year":"2014","unstructured":"Cheon D-J, Tong Y, Sim M-S, Dering J, Berel D, Cui X et al (2014) A collagen-remodeling gene signature regulated by TGF-\u03b2 signaling is associated with metastasis and poor survival in serous ovarian cancer. Clinical cancer research. 20(3):711\u2013723","journal-title":"Clinical cancer research."},{"issue":"1","key":"11394_CR65","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/jcp.30562","volume":"237","author":"G Mannino","year":"2022","unstructured":"Mannino G, Russo C, Maugeri G, Musumeci G, Vicario N, Tibullo D et al (2022) Adult stem cell niches for tissue homeostasis. J Cell Physiol 237(1):239\u2013257","journal-title":"J Cell Physiol"},{"issue":"1","key":"11394_CR66","first-page":"233","volume":"13","author":"F Ju","year":"2022","unstructured":"Ju F, Atyah MM, Horstmann N, Gul S, Vago R, Bruns CJ et al (2022) Characteristics Cancer Stem Cell Niche Therapeutic Strategies Stem Cell Res. Therapy 13(1):233","journal-title":"Therapy"},{"key":"11394_CR67","doi-asserted-by":"crossref","unstructured":"Qin G, Park E-S, Chen X, Han S, Xiang D, Ren F et al (2023) Distinct niche structures and intrinsic programs of fallopian tube and ovarian surface epithelial cells. Iscience 26(1)","DOI":"10.1016\/j.isci.2022.105861"},{"issue":"6","key":"11394_CR68","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1158\/2159-8290.CD-24-0805","volume":"15","author":"GL Garcia","year":"2025","unstructured":"Garcia GL, Orellana T, Gorecki G, Frisbie L, Baruwal R, Suresh S et al (2025) Aged and BRCA-Mutated stromal cells drive epithelial cell transformation. Cancer Discovery 15(6):1203\u20131224","journal-title":"Cancer Discovery"},{"issue":"5","key":"11394_CR69","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/cancers14051221","volume":"14","author":"B Vezzani","year":"2022","unstructured":"Vezzani B, Carinci M, Previati M, Giacovazzi S, Della Sala M, Gaf\u00e0 R et al (2022) Epigenetic regulation: a link between inflammation and carcinogenesis. Cancers. 14(5):1221","journal-title":"Cancers."},{"key":"11394_CR70","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1126\/science.aav1898","volume":"362","author":"MR Corces","year":"2018","unstructured":"Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W et al (2018) The chromatin accessibility landscape of primary human cancers. Science 362:6413","journal-title":"Science"},{"issue":"5","key":"11394_CR71","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell. 144(5):646\u2013674","journal-title":"Cell."},{"issue":"4","key":"11394_CR72","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1038\/emm.2017.10","volume":"49","author":"M Kim","year":"2017","unstructured":"Kim M, Costello J (2017) DNA methylation: an epigenetic mark of cellular memory. Experimental & molecular medicine. 49(4):e322\u2013e322","journal-title":"Experimental & molecular medicine."},{"key":"11394_CR73","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","volume":"17","author":"S Moran","year":"2016","unstructured":"Moran S, Mart\u00ednez-Card\u00fas A, Sayols S, Musul\u00e9n E, Bala\u00f1\u00e1 C, Estival-Gonzalez A et al (2016) Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol 17:10, 1386\u20131395","journal-title":"Lancet Oncol"},{"key":"11394_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-020-00786-7","volume":"12","author":"P Lo Riso","year":"2020","unstructured":"Lo Riso P, Villa CE, Gasparoni G, Vingiani A, Luongo R, Manfredi A et al (2020) A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. Genome Med 12:1\u201320","journal-title":"Genome Med"},{"issue":"3","key":"11394_CR75","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/cancers5030786","volume":"5","author":"CJ Mariani","year":"2013","unstructured":"Mariani CJ, Madzo J, Moen EL, Yesilkanal A, Godley LA (2013) Alterations of 5-hydroxymethylcytosine in human cancers. Cancers. 5(3):786\u2013814","journal-title":"Cancers."},{"issue":"6","key":"11394_CR76","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/1078-0432.CCR-17-1958","volume":"249","author":"DW Tucker","year":"2018","unstructured":"Tucker DW, Getchell CR, Mccarthy ET, Ohman AW, Sasamoto N, Xu S et al (2018) Epigenetic reprogramming strategies to reverse global loss of 5-hydroxymethylcytosine, a prognostic factor for poor survival in high-grade serous ovarian cancer. Clin Cancer Res 249(6):1389\u20131401","journal-title":"Clin Cancer Res"},{"key":"11394_CR77","doi-asserted-by":"publisher","first-page":"107524","DOI":"10.1016\/j.pharmthera.2020.107524","volume":"210","author":"HD Reavis","year":"2020","unstructured":"Reavis HD, Drapkin R (2020) The tubal epigenome\u2013an emerging target for ovarian cancer. Pharmacol Ther 210:107524","journal-title":"Pharmacol Ther"},{"issue":"11","key":"11394_CR78","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/nm.3336","volume":"19","author":"WL Tam","year":"2013","unstructured":"Tam WL, Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nature medicine. 19(11):1438\u20131449","journal-title":"Nature medicine."},{"issue":"4","key":"11394_CR79","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/0008-5472.CAN-18-2297","volume":"79","author":"J Hooda","year":"2019","unstructured":"Hooda J, Novak M, Salomon MP, Matsuba C, Ramos RI, Macduffie E et al (2019) Early loss of histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer research. 79(4):760\u2013772","journal-title":"Cancer research."},{"issue":"24","key":"11394_CR80","first-page":"5460","volume":"25","author":"K-A Dickson","year":"2016","unstructured":"Dickson K-A, Cole AJ, Gill AJ, Clarkson A, Gard GB, Chou A et al (2016) The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20\/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. Hum Mol Genet 25(24):5460\u20135471","journal-title":"Hum Mol Genet"},{"issue":"10","key":"11394_CR81","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/s12276-023-01090-1","volume":"55","author":"H Machino","year":"2023","unstructured":"Machino H, Dozen A, Konaka M, Komatsu M, Nakamura K, Ikawa N et al (2023) Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas. Experimental Mol Med 55(10):2205\u20132219","journal-title":"Experimental Mol Med"},{"issue":"5","key":"11394_CR82","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s11010-024-05167-x","volume":"480","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Jiang S, Tang R, Chen H, Jia G, Zhou X et al (2025) KMT2A facilitates the epithelial-to-mesenchymal transition and the progression of ovarian cancer. Molecular and cellular biochemistry. 480(5):3001\u20133017","journal-title":"Molecular and cellular biochemistry."},{"issue":"1","key":"11394_CR83","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12032-025-03134-0","volume":"43","author":"M Ghanbari","year":"2025","unstructured":"Ghanbari M, Haghi M, Safaralizadeh R, Baradaran B, Hosseinpour Feizi MA (2025) Silencing KMT2A with SiRNA induces apoptosis and cell cycle arrest in high-grade serous ovarian carcinoma cells by modulating GOF p53-dependent pathways, highlighting its potential as a therapeutic target. Med Oncol 43(1):44. https:\/\/doi.org\/10.1007\/s12032-025-03134-0","journal-title":"Med Oncol"},{"key":"11394_CR84","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature15251","volume":"525","author":"J Zhu","year":"2015","unstructured":"Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M et al (2015) Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525:7568, 206\u2013211","journal-title":"Nature"},{"issue":"2 Part 1","key":"11394_CR85","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","volume":"120","author":"KA Schrader","year":"2012","unstructured":"Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG et al (2012) Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol 120(2 Part 1):235\u2013240","journal-title":"Obstet Gynecol"},{"issue":"2","key":"11394_CR86","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ygyno.2011.10.027","volume":"124","author":"AO Rodr\u00edguez","year":"2012","unstructured":"Rodr\u00edguez AO, Llacuachaqui M, Pardo GG, Royer R, Larson G, Weitzel JN et al (2012) BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecologic oncology. 124(2):236\u2013243","journal-title":"Gynecologic oncology."},{"issue":"23","key":"11394_CR87","first-page":"1694","volume":"98","author":"HA Risch","year":"2006","unstructured":"Risch HA, Mclaughlin JR, Cole DE, Rosen B, Bradley L, Fan I et al (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin\u2013cohort study in Ontario. Can J Natl Cancer Inst 98(23):1694\u20131706","journal-title":"Can J Natl Cancer Inst"},{"issue":"5","key":"11394_CR88","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.ajog.2005.05.005","volume":"193","author":"SS Buys","year":"2005","unstructured":"Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL et al (2005) Ovarian cancer screening in the Prostate, Lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193(5):1630\u20131639","journal-title":"Am J Obstet Gynecol"},{"issue":"22","key":"11394_CR89","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C et al (2011) Effect of screening on ovarian cancer mortality: the Prostate, Lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. Jama. 305(22):2295\u20132303","journal-title":"Jama."},{"issue":"10022","key":"11394_CR90","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK et al (2016) Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet 387(10022):945\u2013956","journal-title":"Lancet"},{"issue":"1","key":"11394_CR91","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ygyno.2013.04.048","volume":"130","author":"Q Zhang","year":"2013","unstructured":"Zhang Q, Hu G, Yang Q, Dong R, Xie X, Ma D et al (2013) A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecologic Oncol 130(1):132\u2013139","journal-title":"Gynecologic Oncol"},{"issue":"1","key":"11394_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-017-0500-7","volume":"9","author":"M Widschwendter","year":"2017","unstructured":"Widschwendter M, Zikan M, Wahl B, Lempi\u00e4inen H, Paprotka T, Evans I et al (2017) The potential of Circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med 9(1):1\u201314","journal-title":"Genome Med"},{"issue":"5","key":"11394_CR93","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/cancers11050591","volume":"11","author":"M Hayashi","year":"2019","unstructured":"Hayashi M, Matsuo K, Tanabe K, Ikeda M, Miyazawa M, Yasaka M et al (2019) Comprehensive serum glycopeptide spectra analysis (CSGSA): A potential new tool for early detection of ovarian cancer. Cancers. 11(5):591","journal-title":"Cancers."},{"issue":"12","key":"11394_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002198","volume":"13","author":"CA Parkinson","year":"2016","unstructured":"Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H et al (2016) Exploratory analysis of TP53 mutations in Circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS medicine. 13(12):e1002198","journal-title":"PLoS medicine."},{"key":"11394_CR95","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2019.01.008","volume":"30","author":"Y-M Kim","year":"2019","unstructured":"Kim Y-M, Lee S-W, Lee Y-J, Lee H-Y, Lee J-E, Choi E-K (2019) Prospective study of the efficacy and utility of TP53 mutations in Circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. J Gynecologic Oncol 30:3","journal-title":"J Gynecologic Oncol"},{"issue":"3","key":"11394_CR96","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/biom10030415","volume":"10","author":"SR Vitale","year":"2020","unstructured":"Vitale SR, Groenendijk FH, Van Marion R, Beaufort CM, Helmijr JC, Jan Dubbink H et al (2020) TP53 mutations in serum Circulating cell-free tumor DNA as longitudinal biomarker for high-grade serous ovarian cancer. Biomolecules. 10(3):415","journal-title":"Biomolecules."},{"issue":"15","key":"11394_CR97","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.3390\/cancers14153697","volume":"14","author":"L Paracchini","year":"2022","unstructured":"Paracchini L, Mannarino L, Beltrame L, Landoni F, Fruscio R, Grassi T et al (2022) Targeted mutational analysis of Circulating tumor DNA to Decipher Temporal heterogeneity of high-grade serous ovarian cancer. Cancers. 14(15):3697","journal-title":"Cancers."},{"issue":"1","key":"11394_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep29831","volume":"6","author":"FR Harris","year":"2016","unstructured":"Harris FR, Kovtun IV, Smadbeck J, Multinu F, Jatoi A, Kosari F et al (2016) Quantification of somatic chromosomal rearrangements in Circulating cell-free DNA from ovarian cancers. Sci Rep 6(1):1\u20139","journal-title":"Sci Rep"},{"issue":"7732","key":"11394_CR99","first-page":"579","volume":"563","author":"SY Shen","year":"2018","unstructured":"Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MH, Chadwick D et al (2018) Sensitive tumour detection and classification using plasma cell-free. DNA Methylomes Nat 563(7732):579\u2013583","journal-title":"DNA Methylomes Nat"},{"issue":"18","key":"11394_CR100","doi-asserted-by":"publisher","first-page":"6476","DOI":"10.1158\/0008-5472.CAN-04-1529","volume":"64","author":"II De Caceres","year":"2004","unstructured":"De Caceres II, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI et al (2004) Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 64(18):6476\u20136481","journal-title":"Cancer Res"},{"key":"11394_CR101","doi-asserted-by":"crossref","unstructured":"Ter Brugge P, Kristel P, Van Der Burg E, Boon U, De Maaker M, Lips E et al (2016) Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. J Natl Cancer Inst 108(11):djw148","DOI":"10.1093\/jnci\/djw148"},{"key":"11394_CR102","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ygyno.2024.01.001","volume":"182","author":"M Weigert","year":"2024","unstructured":"Weigert M, Cui X-L, West-Szymanski D, Yu X, Bilecz AJ, Zhang Z et al (2024) 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer. Gynecologic oncology. 182:82\u201390","journal-title":"Gynecologic oncology."},{"issue":"6","key":"11394_CR103","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","volume":"32","author":"LA Diaz Jr","year":"2014","unstructured":"Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping Circulating tumor DNA. J Clin Oncol 32(6):579","journal-title":"J Clin Oncol"},{"key":"11394_CR104","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/bjc.2013.402","volume":"109","author":"I Otsuka","year":"2013","unstructured":"Otsuka I, Kameda S, Hoshi K (2013) Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity. Br J Cancer 109:3, 603\u2013609","journal-title":"Br J Cancer"},{"issue":"3","key":"11394_CR105","first-page":"295","volume":"63","author":"A Ferenczy","year":"1984","unstructured":"Ferenczy A, Gelfand MM (1984) Outpatient endometrial sampling with endocyte: comparative study of its effectiveness with endometrial biopsy. Obstetrics and gynecology. 63(3):295\u2013302","journal-title":"Obstetrics and gynecology."},{"key":"11394_CR106","doi-asserted-by":"crossref","unstructured":"Lai W, Xie R, Chen C, Lou W, Yang H, Deng L et al (2024) Integrated analysis of scRNA-seq and bulk RNA-seq identifies FBXO2 as a candidate biomarker associated with chemoresistance. HGSOC Heliyon 10(7)","DOI":"10.1016\/j.heliyon.2024.e28490"},{"issue":"30","key":"11394_CR107","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences. 105(30):10513\u201310518","journal-title":"Proceedings of the National Academy of Sciences."},{"issue":"1","key":"11394_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00971-6","volume":"13","author":"M Govindarajan","year":"2020","unstructured":"Govindarajan M, Wohlmuth C, Waas M, Bernardini MQ, Kislinger T (2020) High-throughput approaches for precision medicine in high-grade serous ovarian cancer. J Hematol Oncol 13(1):1\u201320","journal-title":"J Hematol Oncol"},{"key":"11394_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-45317-7","volume":"13","author":"M Niemira","year":"2023","unstructured":"Niemira M, Erol A, Bielska A, Zeller A, Skwarska A, Chwialkowska K et al (2023) Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer. Sci Rep 13:1","journal-title":"Sci Rep"},{"issue":"2","key":"11394_CR110","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/path.4000","volume":"228","author":"Z Liu","year":"2012","unstructured":"Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y et al (2012) MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol 228(2):204\u2013215","journal-title":"J Pathol"},{"issue":"5","key":"11394_CR111","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13029","volume":"54","author":"J Mei","year":"2021","unstructured":"Mei J, Tian H, Huang HS, Hsu CF, Liou Y, Wu N et al (2021) Cellular models of development of ovarian high-grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis. Cell proliferation. 54(5):e13029","journal-title":"Cell proliferation."},{"issue":"1","key":"11394_CR112","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1038\/s41467-020-17030-w","volume":"11","author":"M Knarr","year":"2020","unstructured":"Knarr M, Avelar RA, Sekhar SC, Kwiatkowski LJ, Dziubinski ML, Mcanulty J et al (2020) miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. Nat Commun 11(1):3231","journal-title":"Nat Commun"},{"issue":"1","key":"11394_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-020-00648-1","volume":"13","author":"K Maeda","year":"2020","unstructured":"Maeda K, Sasaki H, Ueda S, Miyamoto S, Terada S, Konishi H et al (2020) Serum Exosomal microRNA-34a as a potential biomarker in epithelial ovarian cancer. J Ovarian Res 13(1):1\u20139","journal-title":"J Ovarian Res"},{"issue":"8","key":"11394_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255804","volume":"16","author":"PD Cirillo","year":"2021","unstructured":"Cirillo PD, Margiotti K, Fabiani M, Barros-Filho MC, Sparacino D, Cima A et al (2021) Multi-analytical test based on serum MiRNAs and proteins quantification for ovarian cancer early detection. PLoS One 16(8):e0255804","journal-title":"PLoS One"},{"issue":"11","key":"11394_CR115","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/1878-0261.12762","volume":"14","author":"E Chirshev","year":"2020","unstructured":"Chirshev E, Hojo N, Bertucci A, Sanderman L, Nguyen A, Wang H et al (2020) Epithelial\/mesenchymal heterogeneity of high-grade serous ovarian carcinoma samples correlates with MiRNA let-7 levels and predicts tumor growth and metastasis. Molecular oncology. 14(11):2796\u20132813","journal-title":"Molecular oncology."}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11394-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:01:31Z","timestamp":1766991691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11394-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11394"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11394-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}